The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic StabilityPhase 4NCT05948267
The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults.
A Phase 4 study testing ketamine- dexmeditomidine admixure and Propofol, Lidocaine and fentanyl in people with The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability, run by Kasr El Aini Hospital at 2 sites in Egypt.
Trial summary
The aim of our study to compare two different doses of Dexmedetomidine added to anesthetic dose of ketamine in the induction of general anesthesia in adult patients regarding the hemodynamic profile, adequacy of hypnosis, intubation conditions and recovery type. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability
- What is being tested?
- ketamine- dexmeditomidine admixure and Propofol, Lidocaine and fentanyl
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 2 sitesEgypt
- Study dates
- 25 May 2023to 15 Nov 2024
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients undergoing elective general surgery. Patients aged >18 years. ASA I and II. Both sexes.
Who cannot join
- All patients undergoing emergency surgery. Patients less than 18 years. History of difficult intubation, abnormal airway examination Cardiac morbidities (impaired contractility with ejection fraction < 50%, heart block, arrhythmias, tight valvular lesions).
- Patients on angiotensin converting enzyme inhibitors and angiotensin receptor blockers medications.
- Patients with uncontrolled hypertension. Patients with allergy of any of the study drugs. Body mass index > 35 kg/m2
Trial locations and contacts
2 sites in 1 country.
Egypt2 sites
Kasr Al Ainy Hospitals
Cairo
Kasr Alainy Hospitals Cairouniversity
Cairo
About this study
Official title: The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults: A Randomized Controlled Comparison of Two Doses
The aim of our study to compare two different doses of Dexmedetomidine added to anesthetic dose of ketamine in the induction of general anesthesia in adult patients regarding the hemodynamic profile, adequacy of hypnosis, intubation conditions and recovery type.
We hypothesize that the use of Ketodex during induction of general anesthesia will produce better control regarding the hemodynamic profiles and quality of intubation than propofol.
Read the detailed description
A randomized, double-blinded, controlled trial. All adult patients (ASA I and II), aged > 18 years old undergoing elective general surgery and meeting the inclusion criteria will be included in the study.
The patients will be divided into 3 equal groups: Propofol group (p), Ketamine-Dexmedetomidine (KD5) group and Ketamine-Dexmedetomidine (KD3) group.
In the operating room; Baseline preoperative arterial pressures (systolic, mean\& diastolic) will be the mean of 3 consecutive readings with 30 seconds apart, recorded in the supine position. HR and oxygen saturation baseline will also be recorded.
drug preparation: Propofol (P) group: Propofol(2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml in 2 separate syringes.
Ketamine-Dexmedetomidine (KD5) group: ketamine (1mg/kg) prepared for concentration 10mg/ml, Dexmedetomidine (0.5microg/kg slow IV) prepared for concentration of 5mic /ml in 2 separate syringes.
Ketamine-Dexmedetomidine (KD3) group: ketamine (1mg/kg) prepared concentration 10mg/ml, Dexmedetomidine (0.3microg/kg slow IV) prepared for concentration of 3mic /ml in 2 separate syringes.
induction of anesthesia: After 3-minutes of preoxygenation, the patients in each group will receive a dose of 0.1ml/Kg boluses of the drugs preparations until achieving clinical loss of consciousness (defined as no response to auditory command and the disappearance of a patient's eyelash reflex).
After loss of consciousness, atracurium 0.5 mg/kg will be administered over 5 seconds, and tracheal intubation will be done after 3 minutes of ventilation through direct laryngoscopy.
The intubation conditions will be graded by the same anesthetist who performed intubation as excellent, good, or poor.
When the trachea is intubated, mechanical ventilation will be applied to obtain SpO2 > 95% and end-tidal CO2 between 30-40 mmHg, and anesthesia will be maintained by 1% isoflurane in air/oxygen admixture. Atracurium maintenance dose of 10 mg will be administered every 20 minutes for maintenance of muscle relaxation.
Any incidence of hypotension (defined as MBP <65 mmHg) will be recorded 20 min after induction. Any episode of hypotension (mean arterial <65 mmHg) will be managed by incremental doses of intravenous ephedrine 5 mg (which will be repeated if hypotension persists for 2 minutes).
Hypertension and tachycardia are defined as mean arterial pressure or heart rate >20% of baseline, respectively. Persistent hypertension (blood pressure increasing after one measurement) will be managed by intravenous 0.25 mg/kg propofol in all groups. Bradycardia (heart rate < 50 bpm) will be managed by 0.5 mg of intravenous atropine.
- post-operative : After recovery of the patient we will record the Incidence of emergence agitation, Recovery time, the modified Alderet score system for postoperative recovery and the incidence of Postoperative Complications (nausea \&vomiting).
The total modified Aldrete score values range from 0 to 12. Scores closer to 0 indicate that the patient is closest to the anesthesia state , Scores of 9 and above indicate that the patient can be discharged and the closer the score is to 12, the higher the chances for all anesthetic, regardless of administering method, to have worn off.
Study outcomes:
- Primary outcome: Incidence of post-induction hypotension defined as a mean arterial pressure MAP < 65 mmHg and/or≤ 70% of baseline reading for > 10 s within the first 20 min after general anesthesia induction.
- Secondary outcome:
Mean arterial pressure, SBP, DBP, heart rate at baseline, immediately after induction, after intubation, then every 2-minute till skin incision.
Total Ephedrine requirements during the period from induction anesthesia to skin incision.
Total Atropine requirements during the period from induction anesthesia to skin incision.
Severe post-induction hypotension (mean arterial pressure ≤60 mmHg), hypertension, bradycardia, and tachycardia during 30 min from induction anesthesia.
The Number of hypotensive episodes. Intubation time (time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation) Response to intubation score. Total dexmedetomidine, ketamine and propofol dose per weight. Recovery time Incidence of emergence agitation using Riker Sedation-Agitation Scale
Statistical analysis:
Sample size justification The incidence of post induction hypotension in a previous study (10) for the control group was 58%. At alpha error of 0.05, we calculated that 96 patients would give 80% power to detect 30% absolute reduction in the incidence of hypotension in the treatment group. However, to allow the comparisons between the control group and each treatment group, an adjusted P (Bonferroni correction) of 0.025 was set for the primary outcome and the required sample size increased to 114 patients (38 patients per group). The number of prepared envelopes will be 123 (41 envelopes per group) to compensate for possible dropouts. The sample size was calculated using MedCalc Software version 14 (MedCalc Software bvba, Ostend, Belgium).
Statistical methods The collected data will be coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 22.0, IBM Corp., Chicago, USA, 2013. Quantitative data will be described as mean±SD (standard deviation) and then compared using an independent t-test. Qualitative data will be described as numbers and percentages and compared using the Chi-square test. The level of significance will be taken at p-value < 0.050 is significant, otherwise is non-significant.
- Being tested
- ketamine- dexmeditomidine admixure, Propofol, Lidocaine and fentanyl
- Keywords
- ketamine-dexmeditomedine mixture, ketodex, general anesthesia, hemodynamic stability, anesthesia induction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ketamine- dexmeditomidine admixureDrug
ketamine in anesthetic dose mixed with two different doses of dexmeditomidine
Propofol, Lidocaine and fentanylDrug
Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
| Study group | Role | What they receive |
|---|---|---|
| Propofol (P) group | Active comparator | Propofol(2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml in 2 separate syringes. Receives: Drug: Propofol, Lidocaine and fentanyl |
| Ketamine-Dexmedetomidine (KD5) group | Active comparator | ketamine (1mg/kg) prepared for concentration 10mg/ml, Dexmedetomidine (0.5microg/kg slow IV) prepared for concentration of 5mic /ml in 2 separate syringes. Receives: Drug: ketamine- dexmeditomidine admixure |
| Ketamine-Dexmedetomidine (KD3) group | Active comparator | ketamine (1mg/kg) prepared concentration 10mg/ml, Dexmedetomidine (0.3microg/kg slow IV) prepared for concentration of 3mic /ml in 2 separate syringes. Receives: Drug: ketamine- dexmeditomidine admixure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of post-induction hypotension
mean arterial pressure MAP < 65 mmHg and/or≤ 70% of baseline reading for > 10 s
Measured: the first 20 min after general anaesthesia induction.
Secondary outcomes (9)
Total Ephedrine requirements
Measured: during the period from induction anesthesia to skin incision. maximum 30 minutes
Total Atropine requirements
Measured: during the period from induction anesthesia to skin incision. max 30 minutes
Severe post-induction hypotension (mean arterial pressure ≤60 mmHg), hypertension, bradycardia, and tachycardia
Measured: during 30 min from induction anesthesia.
The Number of hypotensive episodes
Measured: the 2 hours procedure
Intubation time (time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation)
(time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation) (time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation)
Measured: maximum 5 minutes
Response to intubation score.
Measured: maximum 5 minutes
Total dexmedetomidine, ketamine and propofol dose per weight.
Measured: the whole procedure . 2 hours
Recovery time
Measured: less than 15 minutes
Incidence of emergence agitation using Riker Sedation-Agitation Scale
Measured: 60 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2023
- Study start25 May 2023
- Primary completion30 Oct 2023
- Study completion15 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic StabilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The patients will be divided into 3 equal groups: Propofol group (p), Ketamine-Dexmedetomidine (KD5) group and Ketamine-Dexmedetomidine (KD3) group.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kasr El Aini Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amany Ahmed Eissa, Kasr El Aini Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05948267
- Sponsor's protocol ID
- MS-94-2023
- Status last verified
- Jan 2025
- First submitted
- 15 Jun 2023
- Last updated
- 16 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults: A Randomized Controlled Comparison of Two Doses
- ClinicalTrials.gov ID
- NCT05948267
- Acronym / sponsor ID
- MS-94-2023
- Keywords
- ketamine-dexmeditomedine mixture, ketodex, general anesthesia, hemodynamic stability, anesthesia induction
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Kasr El Aini HospitalUniversity, hospital or other
- Study start
- 25 May 2023 (actual)
- Primary completion
- 30 Oct 2023 (actual)
- Study completion
- 15 Nov 2024 (actual)
- First posted
- 17 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of our study to compare two different doses of Dexmedetomidine added to anesthetic dose of ketamine in the induction of general anesthesia in adult patients regarding the hemodynamic profile, adequacy of hypnosis, intubation conditions and recovery type.
We hypothesize that the use of Ketodex during induction of general anesthesia will produce better control regarding the hemodynamic profiles and quality of intubation than propofol.
Detailed description
A randomized, double-blinded, controlled trial. All adult patients (ASA I and II), aged > 18 years old undergoing elective general surgery and meeting the inclusion criteria will be included in the study.
The patients will be divided into 3 equal groups: Propofol group (p), Ketamine-Dexmedetomidine (KD5) group and Ketamine-Dexmedetomidine (KD3) group.
In the operating room; Baseline preoperative arterial pressures (systolic, mean\& diastolic) will be the mean of 3 consecutive readings with 30 seconds apart, recorded in the supine position. HR and oxygen saturation baseline will also be recorded.
drug preparation: Propofol (P) group: Propofol(2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml in 2 separate syringes.
Ketamine-Dexmedetomidine (KD5) group: ketamine (1mg/kg) prepared for concentration 10mg/ml, Dexmedetomidine (0.5microg/kg slow IV) prepared for concentration of 5mic /ml in 2 separate syringes.
Ketamine-Dexmedetomidine (KD3) group: ketamine (1mg/kg) prepared concentration 10mg/ml, Dexmedetomidine (0.3microg/kg slow IV) prepared for concentration of 3mic /ml in 2 separate syringes.
induction of anesthesia: After 3-minutes of preoxygenation, the patients in each group will receive a dose of 0.1ml/Kg boluses of the drugs preparations until achieving clinical loss of consciousness (defined as no response to auditory command and the disappearance of a patient's eyelash reflex).
After loss of consciousness, atracurium 0.5 mg/kg will be administered over 5 seconds, and tracheal intubation will be done after 3 minutes of ventilation through direct laryngoscopy.
The intubation conditions will be graded by the same anesthetist who performed intubation as excellent, good, or poor.
When the trachea is intubated, mechanical ventilation will be applied to obtain SpO2 > 95% and end-tidal CO2 between 30-40 mmHg, and anesthesia will be maintained by 1% isoflurane in air/oxygen admixture. Atracurium maintenance dose of 10 mg will be administered every 20 minutes for maintenance of muscle relaxation.
Any incidence of hypotension (defined as MBP <65 mmHg) will be recorded 20 min after induction. Any episode of hypotension (mean arterial <65 mmHg) will be managed by incremental doses of intravenous ephedrine 5 mg (which will be repeated if hypotension persists for 2 minutes).
Hypertension and tachycardia are defined as mean arterial pressure or heart rate >20% of baseline, respectively. Persistent hypertension (blood pressure increasing after one measurement) will be managed by intravenous 0.25 mg/kg propofol in all groups. Bradycardia (heart rate < 50 bpm) will be managed by 0.5 mg of intravenous atropine.
- post-operative : After recovery of the patient we will record the Incidence of emergence agitation, Recovery time, the modified Alderet score system for postoperative recovery and the incidence of Postoperative Complications (nausea \&vomiting).
The total modified Aldrete score values range from 0 to 12. Scores closer to 0 indicate that the patient is closest to the anesthesia state , Scores of 9 and above indicate that the patient can be discharged and the closer the score is to 12, the higher the chances for all anesthetic, regardless of administering method, to have worn off.
Study outcomes:
- Primary outcome: Incidence of post-induction hypotension defined as a mean arterial pressure MAP < 65 mmHg and/or≤ 70% of baseline reading for > 10 s within the first 20 min after general anesthesia induction.
- Secondary outcome:
Mean arterial pressure, SBP, DBP, heart rate at baseline, immediately after induction, after intubation, then every 2-minute till skin incision.
Total Ephedrine requirements during the period from induction anesthesia to skin incision.
Total Atropine requirements during the period from induction anesthesia to skin incision.
Severe post-induction hypotension (mean arterial pressure ≤60 mmHg), hypertension, bradycardia, and tachycardia during 30 min from induction anesthesia.
The Number of hypotensive episodes. Intubation time (time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation) Response to intubation score. Total dexmedetomidine, ketamine and propofol dose per weight. Recovery time Incidence of emergence agitation using Riker Sedation-Agitation Scale
Statistical analysis:
Sample size justification The incidence of post induction hypotension in a previous study (10) for the control group was 58%. At alpha error of 0.05, we calculated that 96 patients would give 80% power to detect 30% absolute reduction in the incidence of hypotension in the treatment group. However, to allow the comparisons between the control group and each treatment group, an adjusted P (Bonferroni correction) of 0.025 was set for the primary outcome and the required sample size increased to 114 patients (38 patients per group). The number of prepared envelopes will be 123 (41 envelopes per group) to compensate for possible dropouts. The sample size was calculated using MedCalc Software version 14 (MedCalc Software bvba, Ostend, Belgium).
Statistical methods The collected data will be coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 22.0, IBM Corp., Chicago, USA, 2013. Quantitative data will be described as mean±SD (standard deviation) and then compared using an independent t-test. Qualitative data will be described as numbers and percentages and compared using the Chi-square test. The level of significance will be taken at p-value < 0.050 is significant, otherwise is non-significant.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
- Model description
- The patients will be divided into 3 equal groups: Propofol group (p), Ketamine-Dexmedetomidine (KD5) group and Ketamine-Dexmedetomidine (KD3) group.
| Arm | Type | Receives |
|---|---|---|
| Propofol (P) group | Active comparator | Drug: Propofol, Lidocaine and fentanylPropofol(2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml in 2 separate syringes. |
| Ketamine-Dexmedetomidine (KD5) group | Active comparator | Drug: ketamine- dexmeditomidine admixureketamine (1mg/kg) prepared for concentration 10mg/ml, Dexmedetomidine (0.5microg/kg slow IV) prepared for concentration of 5mic /ml in 2 separate syringes. |
| Ketamine-Dexmedetomidine (KD3) group | Active comparator | Drug: ketamine- dexmeditomidine admixureketamine (1mg/kg) prepared concentration 10mg/ml, Dexmedetomidine (0.3microg/kg slow IV) prepared for concentration of 3mic /ml in 2 separate syringes. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- All patients undergoing elective general surgery. Patients aged >18 years. ASA I and II. Both sexes.
Key exclusion criteria (3 listed)
- All patients undergoing emergency surgery. Patients less than 18 years. History of difficult intubation, abnormal airway examination Cardiac morbidities (impaired contractility with ejection fraction < 50%, heart block, arrhythmias, tight valvular lesions).
- Patients on angiotensin converting enzyme inhibitors and angiotensin receptor blockers medications.
- Patients with uncontrolled hypertension. Patients with allergy of any of the study drugs. Body mass index > 35 kg/m2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ketamine- dexmeditomidine admixureketamine in anesthetic dose mixed with two different doses of dexmeditomidine | Drug | Ketamine-Dexmedetomidine (KD3) group, Ketamine-Dexmedetomidine (KD5) group |
| Propofol, Lidocaine and fentanylPropofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml | Drug | Propofol (P) group |
Primary outcome
Incidence of post-induction hypotension
Time frame: the first 20 min after general anaesthesia induction.
mean arterial pressure MAP < 65 mmHg and/or≤ 70% of baseline reading for > 10 s
9 secondary outcomes
Total Ephedrine requirements
Time frame: during the period from induction anesthesia to skin incision. maximum 30 minutes
Total Atropine requirements
Time frame: during the period from induction anesthesia to skin incision. max 30 minutes
Severe post-induction hypotension (mean arterial pressure ≤60 mmHg), hypertension, bradycardia, and tachycardia
Time frame: during 30 min from induction anesthesia.
The Number of hypotensive episodes
Time frame: the 2 hours procedure
Intubation time (time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation)
Time frame: maximum 5 minutes
Response to intubation score.
Time frame: maximum 5 minutes
Total dexmedetomidine, ketamine and propofol dose per weight.
Time frame: the whole procedure . 2 hours
Recovery time
Time frame: less than 15 minutes
Incidence of emergence agitation using Riker Sedation-Agitation Scale
Time frame: 60 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2025.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing ketamine- dexmeditomidine admixure and Propofol, Lidocaine and fentanyl in people with The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability, run by Kasr El Aini Hospital at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of post-induction hypotension (time frame: the first 20 min after general anaesthesia induction.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2025.